All Type of News
Do multinational companies sign agreements only in English?
“Even if it is a multinational pharmaceutical company, I wonder what the company thinks when issuing contracts only in English while having a business in Korea.”
A well-known multinational pharmaceutical company disg...
Celltrion finds distributor of ‘Truxima & Herzuma’ in North America
A U.S. distributor for the Celltrion’s second and third biosimilars was decided.
A company taking charge in Celltrion products’ overseas marketing, Celltrion Healthcare announced on the 6th it chose a global pharmace...
Merck establishes cutting-edge ‘M Lab Center’ in Song-do, Incheon
On the 6th, Merck announced it will establish M Lab™ Center in one of the fastest-growing biotechnology hub, Song-do, Incheon. The center will provide a sharing experimental environment for close cooperation among Mer...
Lutronic announces R-GEN acquires approval of macular edema treating device
On the 6th, Lutronic(CEO Hae-Ryung Hwang) announced ‘R-GEN’ acquired approval of the world’s first macula treating smart laser from the U.S. FDA. It is the first time for a Korean company to acquire approval of an oph...
Boehringer headquarters, “It is right we notified the cancellation at 7:06pm on 29th”
When it comes to the Hanmi Pharm’s technology export agreement cancellation, the opposite party of the cancellation, Boehringer Ingelheim, has released an official position.
According to a report on the 6th, Boehring...
‘Actualized’ rebate investigation on multinational companies
The industry is paying attention to the Novartis’ rebate crisis since it might be extended to investigations on other multinational pharmaceutical companies.
It was observed the authorities of the Ministry of Health ...
Hanmi Pharm’s side effect incident causes issues to devaluate efforts in new drug dev
While some raise voices to derogate the accumulated performance of the pharmaceutical industry based on the case of Hanmi Pharm having side effects on its antibody, some said the Hanmi Pharm’s case should not be a rea...
Boehringer cancelled agreement with Hanmi because of competing drug’s excellence
It was pointed out Boehringer Ingelheim decided to cancel the technology introduction agreement of ‘olmutinib’ with Hanmi Pharm because of its side effects and excellent results of other competing drugs.
Hyundai Secu...
Pharma companies’ desperate measures, “Work with plain clothes”
Since the enforcement of the Kim Young-Ran Law, medical representatives of pharmaceutical company have been under lots of stress. Even if they are following the law right, they are having trouble meeting doctors showi...
Pharma companies’ various measures to respond to Kim Young-Ran Law
Pharmaceutical companies have prepared for various ‘sales guidelines’ to response to the Kim Young-Ran Law which has been enforced from the 28th next month.
On a basis of exceptions(food & beverage for KRW 30 thousan...
Which are outstanding tetravalent vaccines even for the young?
Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer
Who will be the next Pharmaceutical Safety Bureau Director?
Celltrion completes clinical trials for Remsima SC for European approval
Sales listed pharmas made in the first half of the year
March
January
February
March
April
May
June
July
August
September
October
November
December
2025
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
23 | 24 | 25 | 26 | 27 | 28 | 1 |
2 | 3 | 4 | 5 | 6 | 7 | 8 |
9 | 10 | 11 | 12 | 13 | 14 | 15 |
16 | 17 | 18 | 19 | 20 | 21 | 22 |
23 | 24 | 25 | 26 | 27 | 28 | 29 |
30 | 31 | 1 | 2 | 3 | 4 | 5 |
00:00
01:00
02:00
03:00
04:00
05:00
06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
23:00
